ClinicalTrials.gg

Program

RET Inhibitor FHND5071

In Sino Biopharmaceutical’s pipeline, RET抑制剂. Its studies are led by Sino Biopharmaceutical.

Furthest: phase 1, since Mar 29, 20231 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical10 open or runningphase 1since Mar 29, 2023Mar 29, 2023none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as FHND5071, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 29, 2023First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05818917 · 80 enrolled · China

TargetBeta

“RET抑制剂”the company's pipeline, read by Claude · source

Other programs on RET

ProgramCompanyFurthest phaseStudies
regorafenibruleBayerphase 440
selpercatinibruleEli Lillyphase 419
pralsetinibruleHoffmann-La Rochephase 47
quizartinibruleDaiichi Sankyophase 322
RET Inhibitor HS-10365Hansoh Pharmaceutical Groupphase 23
TRK/RET Inhibitor ND-003ruleshenzhen-newdel-biotech-co-ltdphase 23

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05818917Advanced Solid Tumors · China1UNKNOWNDec 31, 202380

How it is read

Names in the registry

  • “FHND5071”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.